Illumina Launches the VeriSeq™ NIPT Solution in Europe
Illumina, Inc. (NASDAQ: ILMN) today announced the launch of the VeriSeq™ NIPT Solution, a CE-IVD marked next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT), including CE-IVD marked library prep and analysis software, which enables laboratories in the European Union to bring efficient, highly accurate NIPT in-house. The automated comprehensive solution allows laboratories to screen for certain fetal chromosomal abnormalities in approximately one day.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170409005007/en/
VeriSeq™ NIPT Solution (Photo: Business Wire)
The VeriSeq™ NIPT Solution provides accurate information about fetal chromosome status as early as 10 weeks gestation using a single maternal blood draw. This noninvasive screen yields results for trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), as well as certain sex chromosome-related disorders. Due to its high-sensitivity and high-specificity (low false-positive and false-negative rates), NGS-based NIPT minimizes the need for invasive testing procedures.
"As a proud partner of Illumina, we are thrilled to soon use the new VeriSeq™ NIPT protocol to power our NIPT test, Serenity,” said Tony Gordon, PhD, Vice President of Business Development for CooperGenomics. "The advances offered by VeriSeq™ NIPT will allow us to provide results to our clinical partners faster, with high sensitivity and minimal test failures.”
By leveraging Illumina paired-end sequencing by synthesis chemistry and incorporating innovations in workflow, instruments and software, the VeriSeq™ NIPT Solution makes NGS-based NIPT accessible to any laboratory. The automated, reliable solution provides reagents, instruments, installation and training, and offers unprecedented turnaround times; laboratories can process up to 96 samples in approximately one day. To demonstrate performance, Illumina conducted a rigorous supporting clinical accuracy study of over 3,100 maternal samples which determined that the VeriSeq™ NIPT Solution not only provided highly sensitive and specific results for trisomies 21, 13 and 18, but also demonstrated a high concordance for the sex chromosomal aneuploidies reported.
“The VeriSeq™ NIPT Solution offers a rapid workflow and unprecedented automation that revolutionizes NIPT. With this validated, CE-IVD marked solution featuring CE-IVD library prep and analysis software, customers can now access highly reliable NGS-based NIPT in their own labs,” said Jeff Hawkins, Vice President and General Manager of Reproductive Genetic Health at Illumina. “With this new solution, laboratories can feel confident that they are providing expectant parents with a highly reliable technology that enables accurate results.”
The VeriSeq™ NIPT Solution is available for order and is now shipping. For more information, visit www.illumina.com/VeriSeqNIPTEU.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected availability dates for new products and services and FDA submission dates and intentions for certain products and services. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services, and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Swiss Wearable Brand MyKronoz Breaks Worldwide Records with its Hybrid Smartwatch ZeTime, on the Sidelines of a Challenging Baselworld 201822.3.2018 16:32 | Pressemelding
On the sidelines of a downsized Baselworld 2018, MyKronoz, the premier watchmaking brand of the smart generation today announces record-breaking crowdfunding results of its hybrid smartwatch ZeTime, with more than $8,000,000 raised in less than a year. The international success of its unique and groundbreaking flagship wearable is followed by the release of a new digital video campaign “I’m a watch; I’m a smartwatch”. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180322005963/en/ MyKronoz ZeTime Petite & Regular top $8M in crowdfunding (Photo: Business Wire) After a historic 35-days Kickstarter campaign launched in March 2017, ZeTime has pursued, since then, its crowdfunding journey on a variety of international and local platforms: Indiegogo, Makuake in Japan, Zec Zec in Taïwan, Wadiz in Korea and on the leading chinese e-commerce website JD.com. Further to this online momentum, MyKronoz has successfully shipped to over 10
Redwood Software Announces First Industry Robotic Licensing Model to Revolutionize Transparent Marketplace Pricing22.3.2018 14:59 | Pressemelding
Redwood Software, the pioneer behind ‘The Robotic Enterprise’, today announced the launch of a revolutionary new robotic licensing model, where customers only pay for the robotic services they consume within their business. Available now, this new licensing model allows customers to directly compare the costs of manual work against processes that are robotized. With the unique Robotic Service Charge, Redwood only charges for the delivery of a robotic service, equivalent to a unit of work that can done by a person (send an email, download a report, reconcile two reports etc.). Redwood delivers a catalogue of 35,000 of these ready built robotic services that can be linked together by business users in a visual plug and play interface. End-to-end business processes can be modelled, robotized, tested and deployed without cost and risk. Only when the robotic service is consumed is a charge made, always replacing work that would otherwise be done manually. Within the Robotic Service Charge,
German Chemical Major Covestro Awards L&T Technology Services Multi-Million Dollar ER&D Project22.3.2018 14:34 | Pressemelding
Germany’s Covestro, a world-leading manufacturer of high-tech polymer materials, has chosen L&T Technology Services Limited (NSE: LTTS), as one of its major engineering services partners to implement digitalization based Engineering Programs across Covestro’s global locations. L&T Technology Services, a global leading pureplay ER&D services company, has been awarded a multi-million dollar contract by Covestro to execute these engineering transformational programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180322005784/en/ (L to R) Amit Chadha, President Sales & Business Development and Member of the Board, LTTS, Ferry Feldbrugge, Head of Global Projects & Engineering and Global Technical Contracting, Covestro and Stephan Krebber, Program Director, OSI2020 Program, Covestro signing the Master Service Agreement for Digital Transformation and Global Standardization Programs (Photo: Business Wire) Covestro is running a digi
The Saga Foundation Announces Its Plan to Create a Non-Anonymous, Reserve-Backed Digital Currency22.3.2018 13:00 | Pressemelding
The Saga Foundation (saga.org) announces today its mission to create Saga (SGA), the first non-anonymous blockchain-based digital currency. The currency is designed with a tamed volatility mechanism. These characteristics can set the ground for the currency to become a store of value and a medium of exchange. Saga is designed to address legitimate concerns expressed by policy makers, regulators and market participants regarding cryptocurrencies; mainly their anonymity, lack of underlying value and high volatility. Saga holders must satisfy full KYC (Know Your Customer) qualification and AML (Anti Money Laundering) requirements under Swiss law. With such disclosures, Saga resolves concerns about participant accountability, an issue that is generally raised regarding cryptographic currencies. Saga aims to promote a low-volatility environment, combining the virtues of blockchain technologies with algorithmic representations of financial tools. For this reason, Saga is backed by a variable
boohoo.com Celebrates the Launch of Their Spring Collection & the Zendaya Edit with a 90s Throwback Block Party!22.3.2018 12:48 | Pressemelding
This evening, international etailer, boohoo.com, celebrated the launch of their newest Spring collection at an exclusive launch party in Los Angeles at The Dream Hollywood for media, influencers, and friends of the brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180322005667/en/ boohoo.com Celebrates the Launch of their Spring Collection & the Zendaya Edit with a 90s Throwback Block Party! Taking note from the product aesthetic, the event served as the ultimate 90s nostalgia trip with bright and bold décor from neon signs to giant boom boxes and life-size cassette tapes. Throughout the night, guests engaged in various activations including 90s dance lessons, cocktail making, cooking lessons, firework displays and interactive arcade games. Attendees also enjoyed 90s-inspired catering including retro treats Bubble Tape and Candy Necklaces, as well as Slush Puppies and Sunny D cocktails. Surprise musical guests, Snoop Dog
Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal Phase 2 PACE Trial in Blood22.3.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that final data from the pivotal Phase 2 PACE clinical trial of ICLUSIG (ponatinib) in refractory chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) were published in Blood . The manuscript is available online today and will be included in a future print edition of Blood. The final five-year results support ICLUSIG as an effective treatment option for patients with chronic-phase CML (CP-CML) whose prior therapies have failed. ICLUSIG, a tyrosine kinase inhibitor (TKI) with potent activity against native and mutant forms of BCR-ABL1 (an abnormal tyrosine kinase that is expressed in CML and Ph+ ALL), received full approval from the U.S. Food and Drug Administration in 2016. ICLUSIG is indicated for the treatment of adult patients with CML or Ph+ ALL for whom no other TKI is indicated, including those with T315I-positive CML or T315I-positive Ph+ ALL. ICLUSIG is not ind